- Production technology and production device of c`yproterone acetate
-
The invention discloses a cyproterone acetate production device. The cyproterone acetate production device comprises a reaction kettle, an elutriation kettle, a centrifugal machine, a concentration kettle, a decoloration kettle and a drying device, wherein the drying device comprises an outer cylinder, a drying cylinder and an inner cylinder; a motor is arranged on the bottom surface of the outercylinder; exhausting fan blades, cylinder type impellers and vortex impellers are arranged on a rotating shaft of the motor; the exhausting fan blades are arranged between the drying cylinder and thebottom surface of the outer barrel; the cylinder type impellers are arranged between the drying cylinder and the inner cylinder; the vortex impellers are arranged at the bottom of the inner cylinder;an infrared ray heating pipe is arranged on the top surface of the inner cylinder; a rotating air purifying ring is arranged at the upper end of a sandwiching chamber of the outer cylinder; a mountingring is arranged on a top plate, and a gear ring is arranged in the mounting ring; screw rods and slide bars are arranged at the bottom of the mounting ring annularly and evenly in a staggering manner; pinions are arranged on the tops of the screw rods and are meshed with the gear ring; one of the screw rods is connected to an operating crank; a turnover cover is arranged on the top end of the mounting ring; and a tray is arranged on the screw rods. The cyproterone acetate production device can reduce the preparation time of intermediate products in the production process of cyproterone acetate, and realizes the rapid high-quality production of the cyproterone acetate.
- -
-
Paragraph 0091; 0093
(2019/01/08)
-
- Preparation process of cyproterone acetate (by machine translation)
-
The invention relates to a preparation process of cyproterone acetate, which comprises the following steps: ketal reaction; cyclopropanecarboxylic hydrolysis reaction; acetyl reaction; epoxy reaction; chlorinated reaction; a cyclization reaction; the invention can overcome the original process product is difficult to solve in the benzene remains the problem of, and the start is simple in raw material, reaction is stable, the total yield is high. (by machine translation)
- -
-
-
- Further syntheses of cyproterone acetate
-
The present invention relates to improved methods for synthesising cyproterone acetate (17α-Acetoxy-6-chloro-1α, 2α-methylene-4,6-pregnadiene-3,20-dione) from solasodine. The methods of the invention are shorter as those of the prior art and therefore more economic.
- -
-
Page/Page column 3; 20; 30
(2010/02/07)
-
- Pharmaceutical combined preparation, kit and method for hormonal contraception
-
PCT No. PCT/DE96/01192 Sec. 371 Date Jun. 3, 1998 Sec. 102(e) Date Jun. 3, 1998 PCT Filed Jun. 27, 1996 PCT Pub. No. WO97/01342 PCT Pub. Date Jan. 16, 1997The present invention describes a two-stage pharmaceutical combined preparation for hormonal contraception containing at least 30 daily unit doses, which preparation, in its first stage, comprises as hormonal active ingredient a combination of an oestrogen preparation and, in a dose that is at least sufficient to inhibit ovulation, a gestagen preparation, in single stage form and, in the second stage comprises as hormonal active ingredient an oestrogen preparation only, wherein the first stage comprises a minimum of 25 and a maximum of 77 daily discrete or continuous unit doses and the second stage comprises 5, 6 or 7 daily discrete or continuous unit doses, and wherein the total number of daily units is equal to the total number of days of the desired cycle of a minimum of 30 and a maximum of 84 days. This combined preparation, in the form of a monthly pack, which is used for female fertility control, permits as low as possible an oestrogen content in each individual unit dose and also has a low total hormone content per cycle of administration, with high contraceptive reliability, low incidence of follicle development, and satisfactory cycle control with reliable avoidance of intermediate bleeding as well as undesired side effects.
- -
-
-
- Pharmaceutical combination preparation for hormonal contraception
-
The invention provides a pharmaceutical combination preparation with two hormone components in a packaging unit and intended for time-sequential oral administration, comprising a number of daily dosage units physically separate and individually removable in the packaging unit, whereby as a hormonal active ingredient a first hormone component contains in combination an estrogen preparation and in at least a dosage that is sufficient to inhibit ovulation a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation, whereby the first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4, 3 or 2 daily units, and between these two hormone components, 2 or 1 active ingredient-free daily units are present or 2 or 1 blank pill days are indicated, and the total number of hormone daily units and the active ingredient-free daily units or the blank pill days is equal to the total number of days of the desired cycle, but at least 28 days in length. This combination preparation is useful for female birth control, and allows for an estrogen content that is as low as possible in each individual dosage unit and also has a low total hormone content per administration cycle, with high contraceptive reliability, low incidence of follicular development, and satisfactory cycle control, with reliable avoidance of intracyclic menstrual bleeding as well as of undesirable side-effects.
- -
-
-
- Pharmaceutical combination preparation for hormonal contraception
-
A pharmaceutical combination preparation with two hormone components that are manufactured physically separately in a packaging unit and that are intended for time-sequential oral administration, which in each case consist of a number of daily dosage units that are placed physically separately and are individually removable in the packaging unit. As a hormonal active ingredient, a first hormone component contains in combination an estrogen preparation and, in at least a dosage that is sufficient to inhibit ovulation, a gestagen preparation, and as a hormonal active ingredient the second hormone component contains only an estrogen preparation. The first hormone component comprises 23 or 24 daily units and the second hormone component comprises 4 to 10 daily units. The total number of hormone daily units is equal to the total number of days of the desired cycle, but at least 28 days in length. This combination preparation is used for female birth control, and allows for an estrogen content that is as low as possible in each individual dosage unit and also has a low total hormone content per administration cycle, with high contraceptive reliability, low incidence of follicular development, and satisfactory cycle control, with reliable avoidance of intracyclic menstrual bleeding as well as of undesirable side-effects.
- -
-
-
- Process for the production of 17α-acyloxy-6-chloro-1α,2α-m
-
A process for the production of 17α-acyloxy-6-chloro-1α,2α-methylene-3,20-diones of the general Formula I STR1 wherein R represents an alkyl group with up to 5 carbon atoms or a phenyl group, is characterized in that a compound of general Formula II STR2 wherein R has the meaning indicated above, is reacted, in the presence of a strong acid, with a compound of general formula III STR3 wherein R' is a hydrogen atom or an alkyl group with up to 4 carbon atoms and R represents alkoxy groups, alkylthio groups or dialkylamino groups with 1 to 4 carbon atoms in each alkyl radical.
- -
-
-